Shupak A, Gordon C R, Spitzer O, Mendelowitz N, Melamed Y
Motion Sickness and Human Performance Laboratory, Israeli Naval Hyperbaric Institute, Haifa.
Pharmatherapeutica. 1989;5(6):365-70.
A study was carried out in 68 otherwise healthy male naval crew members to assess the long-term effectiveness and side-effects of routine transdermal scopolamine administration for the prevention of seasickness. The transdermal patches were applied to the mastoid process before each sailing and the subjects generally used 2 patches a week. Check-ups were made every 3 months over a period of 3 years. The average reported seasickness severity (on a scale of 0 to 7) after 6 months at sea prior to the administration of transdermal scopolamine was 5.64 +/- 0.11 (mean +/- S.E.M.), in comparison with 3.14 +/- 0.23 post-administration (p less than 0.001). A significant improvement was found in the self-estimated performance at sea whilst receiving the drug: 65.7% +/- 3.38% (mean +/- S.E.M.), compared to 25% +/- 2.24% beforehand (p less than 0.001). Contact dermatitis precluded the use of transdermal scopolamine in 3 (4.4%) subjects. The only other significant side-effect was dryness of mucous membranes. In conclusion, transdermal scopolamine was found to be effective in the prevention of seasickness and improvement of performance at sea during 3 years of follow-up and routine administration of the drug was not complicated either by severe side-effects or by performance disturbances.
一项针对68名身体健康的男性海军船员开展的研究，旨在评估常规经皮给予东莨菪碱预防晕船的长期有效性和副作用。在每次航行前将透皮贴剂贴于乳突，受试者通常每周使用2片。在3年期间每3个月进行一次检查。在给予经皮东莨菪碱前，海上6个月期间报告的平均晕船严重程度（0至7级）为5.64±0.11（均值±标准误），相比之下，给药后为3.14±0.23（p<0.001）。在接受药物治疗期间，自我评估的海上表现有显著改善：65.7%±3.38%（均值±标准误），而之前为25%±2.24%（p<0.001）。3名（4.4%）受试者因接触性皮炎而无法使用经皮东莨菪碱。唯一的其他显著副作用是粘膜干燥。总之，在3年的随访中，发现经皮东莨菪碱在预防晕船和改善海上表现方面有效，并且该药物的常规给药既没有因严重副作用也没有因性能干扰而变得复杂。
